Format

Send to

Choose Destination
J Neural Transm Suppl. 2004;(68):117-22.

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

Author information

1
District Hospital, Taufkirchen/Vils, Germany.

Abstract

According to the excitotoxicity hypothesis, neurotoxicity due to glutamate is regarded as potential factor in the progredient neurodegeneration of Huntington's disease (HD). Memantine, as a glutamate receptor antagonist, should counteract this mechanism. Its effectiveness (up to 30 mg/day) with regard to retardation of progression was thus examined in 27 HD patients in a two year, open and multicentre trial. The results suggest that memantine treatment of HD may be useful in terms of retardation of the progression of the disorder.

PMID:
15354397
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center